drugset / Trial / NCT02194465
A Study of LY2623091 in Participants With High Blood Pressure
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
Timeline
- Start
- 2014-08
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2623091 | Small molecule | 6 mg | Oral |
| Subject | LY2623091 | Small molecule | 13 mg | Oral |
| Subject | LY2623091 | Small molecule | 24.5 mg | Oral |
| Comparator | Spironolactone | Small molecule | 50 mg | Oral |
| Subject | Tadalafil | Small molecule | 20 mg | Oral |